IL164429A0 - Novel peptides and the application thereof in therapy - Google Patents

Novel peptides and the application thereof in therapy

Info

Publication number: IL164429A0
Authority: IL; Israel
Prior art keywords: gln; cytokine; microg; residues; beta
Prior art date: 2002-04-10

Application number

IL16442904A

Other languages

English (en)

Original Assignee

Vaxconsulting

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-10

Filing date

2004-10-05

Publication date

2005-12-18

2004-10-05 Application filed by Vaxconsulting filed Critical Vaxconsulting

2005-12-18 Publication of IL164429A0 publication Critical patent/IL164429A0/xx

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
238000002560 therapeutic procedure Methods 0.000 title 1
108090000695 Cytokines Proteins 0.000 abstract 3
102000004127 Cytokines Human genes 0.000 abstract 3
101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 abstract 2
150000001413 amino acids Chemical class 0.000 abstract 2
230000002163 immunogen Effects 0.000 abstract 2
102000001327 Chemokine CCL5 Human genes 0.000 abstract 1
108010055166 Chemokine CCL5 Proteins 0.000 abstract 1
150000008574 D-amino acids Chemical class 0.000 abstract 1
238000002965 ELISA Methods 0.000 abstract 1
102000006992 Interferon-alpha Human genes 0.000 abstract 1
108010047761 Interferon-alpha Proteins 0.000 abstract 1
241000699670 Mus sp. Species 0.000 abstract 1
230000010933 acylation Effects 0.000 abstract 1
238000005917 acylation reaction Methods 0.000 abstract 1
238000007792 addition Methods 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
230000003266 anti-allergic effect Effects 0.000 abstract 1
230000002456 anti-arthritic effect Effects 0.000 abstract 1
230000001088 anti-asthma Effects 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
230000036436 anti-hiv Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000002682 anti-psoriatic effect Effects 0.000 abstract 1
230000003356 anti-rheumatic effect Effects 0.000 abstract 1
239000000924 antiasthmatic agent Substances 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
239000003435 antirheumatic agent Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
102000003675 cytokine receptors Human genes 0.000 abstract 1
108010057085 cytokine receptors Proteins 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
238000012217 deletion Methods 0.000 abstract 1
230000037430 deletion Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000007306 functionalization reaction Methods 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000004048 modification Effects 0.000 abstract 1
238000012986 modification Methods 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000003472 neutralizing effect Effects 0.000 abstract 1
238000007363 ring formation reaction Methods 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

IL16442904A 2002-04-10 2004-10-05 Novel peptides and the application thereof in therapy IL164429A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0204464A FR2838444B1 (fr)	2002-04-10	2002-04-10	Nouveaux peptides et leur application en therapeutique
PCT/FR2003/001120 WO2003084979A2 (fr)	2002-04-10	2003-04-09	Peptides et leur application en therapeutique

Publications (1)

Publication Number	Publication Date
IL164429A0 true IL164429A0 (en)	2005-12-18

Family

ID=28459716

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16442904A IL164429A0 (en)	2002-04-10	2004-10-05	Novel peptides and the application thereof in therapy

Country Status (20)

Country	Link
US (6)	US7393523B2 (de)
EP (3)	EP2314312A3 (de)
JP (1)	JP2005530723A (de)
KR (1)	KR101101004B1 (de)
CN (1)	CN1649898A (de)
AT (1)	ATE526985T1 (de)
AU (1)	AU2003260031B2 (de)
CA (1)	CA2480996C (de)
DK (1)	DK2314311T3 (de)
ES (2)	ES2550030T3 (de)
FR (1)	FR2838444B1 (de)
IL (1)	IL164429A0 (de)
MA (1)	MA27191A1 (de)
MX (1)	MXPA04009841A (de)
NZ (1)	NZ536351A (de)
RU (1)	RU2326125C2 (de)
SI (1)	SI2314311T1 (de)
TN (1)	TNSN04200A1 (de)
WO (1)	WO2003084979A2 (de)
ZA (1)	ZA200408451B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7422743B2 (en) *	2000-05-10	2008-09-09	Schering Corporation	Mammalian receptor protein DCRS5;methods of treatment
FR2859725B1 (fr)	2003-09-16	2006-03-10	Neovacs	Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
MXPA06009805A (es) *	2004-02-27	2007-04-02	Vaxconsulting	Peptidos de interleucina 1 beta y factor de necrosis tumoral alfa y metodo de tratamiento utilizando los mismos.
CN101267834B (zh)	2005-09-28	2013-06-05	赛托斯生物技术公司	白介素-1偶联物及其用途
NZ592943A (en) *	2008-11-17	2012-09-28	Uinv Kobenhavns	Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
US9301997B2 (en)	2009-09-21	2016-04-05	Peptinov Sas	Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides
WO2011143280A2 (en)	2010-05-11	2011-11-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling
CN110133296B (zh) *	2012-03-18	2022-03-25	镜株式会社	疾病样品分析装置、分析系统及分析方法
US9376489B2 (en)	2012-09-07	2016-06-28	Novartis Ag	IL-18 binding molecules
AU2016271857B2 (en) *	2015-06-03	2020-05-28	Affiris Ag	IL-23-P19 vaccines
KR102210543B1 (ko) *	2017-10-13	2021-02-01	주식회사 나이벡	고효율 줄기세포 선별을 위한 grp78 유래 펩타이드
AU2020275076A1 (en) *	2019-05-10	2021-11-25	Bimyo GmbH	BNIP3 peptides for treatment of reperfusion injury
WO2023161528A1 (en)	2022-02-28	2023-08-31	Tridem Bioscience Gmbh & Co Kg	A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4772685A (en) *	1985-10-02	1988-09-20	Merck & Co., Inc.	Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US5013824A (en) *	1985-11-19	1991-05-07	Schering Corporation	Human interleukin-4 peptides and conjugates thereof
DE3841761A1 (de) *	1988-12-12	1990-06-13	Basf Ag	Neue tnf-peptide
ES2085983T3 (es) *	1989-12-20	1996-06-16	Schering Corp	Antagonistas de anticuerpos de la interleuquina-4 humana.
EP0521918A4 (en) *	1990-03-19	1993-05-05	Peptide Technology Ltd	Anti-tumour peptides
FR2677654B1 (fr) *	1991-06-17	1995-11-17	Pasteur Merieux Serums Vacc	Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
US6117974A (en) *	1991-10-02	2000-09-12	Peptor Limited	Libraries of backbone-cyclized peptidomimetics
US5494662A (en) *	1992-04-27	1996-02-27	Ono Pharmaceutical Co., Ltd.	Stimulator for bone formation
AU4554493A (en) *	1992-07-07	1994-01-31	Eleanor N. Fish	Interferon receptor binding peptides
US5770191A (en) *	1995-05-24	1998-06-23	University Of Florida	Active C-terminal peptides of interferon--gamma and their use
US5994292A (en) *	1995-05-31	1999-11-30	The United States Of America As Represented By The Department Of Health And Human Services	Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
IT1277926B1 (it) *	1995-09-01	1997-11-12	Angeletti P Ist Richerche Bio	Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
JP2001511649A (ja) *	1997-02-07	2001-08-14	トーマス・ジェファーソン・ユニバーシティ	サイトカインレセプターガンマ鎖のペプチド模倣物
IT1291353B1 (it) *	1997-05-12	1999-01-07	San Raffaele Centro Fond	Peptidi con attivita' antivirale
JP2002516069A (ja) *	1997-09-30	2002-06-04	ファルマシア・アンド・アップジョン・カンパニー	Ｔｎｆ関連死リガンド
NZ513507A (en) *	1999-02-08	2003-08-29	Medvet Science Pty Ltd	Cytokine-binding domain
WO2000053219A2 (en) *	1999-03-11	2000-09-14	Entremed, Inc.	Compositions and methods for treating cancer and hyperproliferative disorders
US7129072B1 (en) *	1999-08-30	2006-10-31	New York University	Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
US6420346B1 (en) *	2000-02-07	2002-07-16	Rappaport Family Institute For Research In The Medical Sciences	Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
WO2002044197A2 (en) *	2000-12-01	2002-06-06	Fish Eleanor N	Cytokine receptor binding peptides
US20030166589A1 (en) *	2001-06-05	2003-09-04	Nathan Karin	Method and pharmaceutical composition for the treatment of multiple sclerosis

2002
- 2002-04-10 FR FR0204464A patent/FR2838444B1/fr not_active Expired - Lifetime
2003
- 2003-04-09 WO PCT/FR2003/001120 patent/WO2003084979A2/fr not_active Ceased
- 2003-04-09 EP EP10183961A patent/EP2314312A3/de not_active Withdrawn
- 2003-04-09 ES ES10183953.8T patent/ES2550030T3/es not_active Expired - Lifetime
- 2003-04-09 ES ES03740584T patent/ES2375053T3/es not_active Expired - Lifetime
- 2003-04-09 KR KR1020047016042A patent/KR101101004B1/ko not_active Expired - Fee Related
- 2003-04-09 CA CA2480996A patent/CA2480996C/fr not_active Expired - Fee Related
- 2003-04-09 AU AU2003260031A patent/AU2003260031B2/en not_active Ceased
- 2003-04-09 SI SI200332450T patent/SI2314311T1/sl unknown
- 2003-04-09 EP EP10183953.8A patent/EP2314311B1/de not_active Expired - Lifetime
- 2003-04-09 US US10/510,116 patent/US7393523B2/en not_active Expired - Fee Related
- 2003-04-09 MX MXPA04009841A patent/MXPA04009841A/es not_active Application Discontinuation
- 2003-04-09 CN CNA038100606A patent/CN1649898A/zh active Pending
- 2003-04-09 EP EP03740584A patent/EP1492814B1/de not_active Expired - Lifetime
- 2003-04-09 NZ NZ536351A patent/NZ536351A/en not_active IP Right Cessation
- 2003-04-09 AT AT03740584T patent/ATE526985T1/de not_active IP Right Cessation
- 2003-04-09 RU RU2004132871/13A patent/RU2326125C2/ru not_active IP Right Cessation
- 2003-04-09 DK DK10183953.8T patent/DK2314311T3/en active
- 2003-04-09 JP JP2003582175A patent/JP2005530723A/ja active Pending
2004
- 2004-10-01 MA MA27884A patent/MA27191A1/fr unknown
- 2004-10-05 IL IL16442904A patent/IL164429A0/xx unknown
- 2004-10-08 TN TNP2004000200A patent/TNSN04200A1/fr unknown
- 2004-10-19 ZA ZA2004/08451A patent/ZA200408451B/en unknown
2008
- 2008-06-06 US US12/134,743 patent/US7641895B2/en not_active Expired - Lifetime
2009
- 2009-12-01 US US12/628,826 patent/US7892529B2/en not_active Expired - Fee Related
2011
- 2011-01-11 US US13/004,588 patent/US8147819B2/en not_active Expired - Fee Related
2012
- 2012-01-31 US US13/362,234 patent/US8277792B2/en not_active Expired - Fee Related
- 2012-08-24 US US13/593,823 patent/US8529881B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP2314311A2 (de)	2011-04-27
US20100150957A1 (en)	2010-06-17
AU2003260031A1 (en)	2003-10-20
ATE526985T1 (de)	2011-10-15
EP2314312A2 (de)	2011-04-27
EP2314312A3 (de)	2011-08-31
US7892529B2 (en)	2011-02-22
DK2314311T3 (en)	2015-10-12
US7641895B2 (en)	2010-01-05
FR2838444B1 (fr)	2016-01-01
NZ536351A (en)	2007-03-30
CA2480996A1 (fr)	2003-10-16
US8529881B2 (en)	2013-09-10
US20060241286A1 (en)	2006-10-26
ZA200408451B (en)	2006-01-25
TNSN04200A1 (fr)	2007-03-12
ES2375053T3 (es)	2012-02-24
US20080260689A1 (en)	2008-10-23
RU2004132871A (ru)	2005-09-20
MA27191A1 (fr)	2005-01-03
KR20040108709A (ko)	2004-12-24
US8277792B2 (en)	2012-10-02
EP2314311B1 (de)	2015-07-15
EP1492814B1 (de)	2011-10-05
US20120121627A1 (en)	2012-05-17
US7393523B2 (en)	2008-07-01
EP2314311A3 (de)	2011-08-17
FR2838444A1 (fr)	2003-10-17
JP2005530723A (ja)	2005-10-13
AU2003260031B2 (en)	2009-10-29
US8147819B2 (en)	2012-04-03
MXPA04009841A (es)	2005-06-17
CN1649898A (zh)	2005-08-03
CA2480996C (fr)	2016-06-21
WO2003084979A2 (fr)	2003-10-16
US20120321652A1 (en)	2012-12-20
KR101101004B1 (ko)	2011-12-29
WO2003084979A3 (fr)	2004-04-08
SI2314311T1 (sl)	2015-12-31
RU2326125C2 (ru)	2008-06-10
US20110171169A1 (en)	2011-07-14
EP1492814A2 (de)	2005-01-05
ES2550030T3 (es)	2015-11-04

Publication	Publication Date	Title
IL164429A0 (en)	2005-12-18	Novel peptides and the application thereof in therapy
NO914937L (no)	1991-12-19	Immunoaktive peptider og antistoffer samt deres anvendelse ved anti-allergibehandling
GR3030141T3 (en)	1999-08-31	Diphtheria toxin receptor-binding region.
ATE162723T1 (de)	1998-02-15	Die induktion der antikörperantwort gegen eigene proteine mit hilfe fremder t-zellepitope
ATE359817T1 (de)	2007-05-15	Auf n-formyl methionyl peptide basierendem adjuvans für impfstoffe
CY1108282T1 (el)	2014-02-12	Χρηση λιποπεπτιδιου ή λιποπρωτεϊνης ως ανοσοενισχυτικο σε θεραπευτικο ή προφυλακτικο εμβολιασμο
BR0209685A (pt)	2004-07-13	Derivado de um peptìdeo insulinotrópico e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método de produção de derivado de peptìdeo insulinotrópico e uso de um derivado de peptìdeo insulinotrópico e de sais farmaceuticamente aceitáveis
HU9300877D0 (en)	1993-06-28	Method for producing proteines applicables by injection and inducing anti-bodies having neutralizing effect against virus of human immun insufficiency
FI903996A0 (fi)	1990-08-13	Mutanter av humant interleukin-3.
Vichier-Guerre et al.	2004	Synthesis and immunological evaluation of an antitumor neoglycopeptide vaccine bearing a novel homoserine Tn antigen
JP2005530723A5 (de)	2006-05-25
CA1262799A (en)	1989-11-07	Broad spectrum vaccine against gonorrhea
WO2003106487A1 (en)	2003-12-24	Immunogenic conjugates
Jeannin et al.	1993	Immunogenecity and antigenicity of synthetic peptides derived from the mite allergen Der p I
JPH08511508A (ja)	1996-12-03	ボツリヌス毒素ポリペプチドおよびワクチン増強剤としてのその使用
DE69626642D1 (de)	2003-04-17	Cetp zur erhöhung des hdl-cholesterol-gehalts
Herzbeck et al.	1989	Functional and Molecular Characterization of a Monoclonal Antibody against the 165–186 Peptide of Human 1β
Manivel et al.	1991	Interleukin-1 derived synthetic peptide as an added co-adjuvant in vaccine formulations
ATE98962T1 (de)	1994-01-15	Menschliche rhinoviruspeptide.
Babakhin et al.	1996	185 Immunomodulating activity of the extract from high mycelium fungus polyporus squamosus
ATE145335T1 (de)	1996-12-15	Kreuzreaktive immunisierung gegen influenza
RU94046096A (ru)	1996-07-20	Линейные или циклические пептиды, их применение, способы лечения и конъюгаты пептидов
CN115175927A (zh)	2022-10-11	旨在诱导针对白细胞介素-6的免疫应答的免疫原性结合物